Relistor (methylnaltrexone bromide)
- Region
- 🇪🇺 EU
- Active substance
- methylnaltrexone bromide
- Company
- Bausch Health Ireland Limited
- Status
- Authorised
- Therapeutic area
- Opioid-Related Disorders; Constipation
- CHMP opinion
- Thu 24 Apr 2008
- EU approval
- Tue 01 Jul 2008
- Application
- EMEA/H/C/000870
- ATC
- A06AH01
- Official record
- www.ema.europa.eu
Indication
Treatment of opioid-induced constipation in advanced-illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient.
Regulatory milestones
No milestones recorded in the last year.
Follow Relistor
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.